Edwards Lifesciences Announces Strategic Investments
IRVINE, Calif., March 11, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced two strategic transactions involving companies with structural heart disease technologies.
Edwards has invested $35 million in an exclusive right to acquire Corvia Medical, Inc., the developer of the world's first transcatheter device designed to treat heart failure with preserved or mid-range ejection fraction. The company's InterAtrial Shunt Device is designed to provide continuous and dynamic decompression of the left atrium, which may reduce symptoms and slow the progression of heart failure. The therapy has received CE Mark in Europe, and is being studied as part of a Food and Drug Administration pivotal clinical trial.
Separately, Edwards has also acquired certain assets of Mitralign, Inc., including intellectual property and associated clinical and regulatory experience. Mitralign is a developer of an investigational transcatheter annuloplasty system designed to treat functional mitral and tricuspid regurgitation.
Additional terms of these transactions remain confidential. Today's announcement is not expected to impact Edwards' 2019 financial guidance.
About Edwards Lifesciences
Edwards Lifesciences, based in Irvine, Calif., is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world's leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives. For more information, visit www.Edwards.com and follow us on Twitter @EdwardsLifesci.
CONTACT: Media Contact: Sarah Huoh, 949-250-5070; Investor Contact: David K. Erickson, 949-250-6826
